β-Amyloid (22-40) is a peptide fragment of β-Amyloid.

Beta-Amyloid(1-14),mouse,rat is a 1 to 14 fragment of Amyloid-β peptide.

Cl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein.

RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory activities.

Aβ/tau aggregation-IN-1 is a potent Aβ1-42 β-sheets formation and tau aggregation inhibitor. The KD values of Aβ/tau aggregation-IN-1 with Aβ1-42 and tau are 160 μM and 337 μM, respectively. Aβ/tau aggregation-IN-1 can permeate the blood-brain barrier.

Methyl tridecanoate moderately inhibits β-amyloid aggregation. Methyl tridecanoate weakly inhibits acetylcholinesterase (AChE).

AZD4694, a fluorinated β-amyloid (Aβ) plaque neuroimaging PET radioligand, shows high affinity for Aβ fibrils (Kd = 2.3 nM).

Aβ Fibrillization modulator 1 stabilizes Aβ monomers.

BuChE-IN-2 is an excellent butyrylcholinesterase (BuChE) inhibitor (IC50s of 1.28 μM and 0.67 μM for BuChE and NO). BuChE-IN-2 can inhibit the aggregation of Aβ, ROS formation and chelate Cu2+, exhibiting proper blood-brain barrier (BBB) penetration. BuChE-IN-2 has potential to research Alzheimer’s disease.

anle145c is a small molecule inhibitor of amyloid aggregation and formation, inhibits human islet amyloid polypeptide (hIAPP)-induced death of INS-1E cells.anle145c has a special mode of action in which anle145c-stabilized oligomers act as a thermodynamic sink for the preferred aggregation state of hIAPP and anle145c.anle145c prevents hIAPP fibril formation in solution, and converts preformed hIAPP fibrils into non-toxic oligomers.anle145c is a promising candidate to inhibit protein aggregation in case of T2DM.

YX-A-1 is a small-molecule modulator of human islet amyloid polypeptide (hIAPP) assembly, specifically enhances amyloid formation; YX-A-1 accelerates wt hIAPP assembly, even when added in substoichiometric concentration ratios (e.g. at a peptide:YX-A-1 molar ratio of 1:0.5 the t50 is reduced ~1.5-fold). YX-A-1 is a useful chemical tools to study hIAPP aggregation.

YX-I-1 is a small-molecule modulator of human islet amyloid polypeptide (hIAPP) assembly, specifically inhibits amyloid formation; YX-I-1 inhibits the aggregation of wt hIAPP, extending the t50 from 15.1 ± 0.2 h to 23.4 ± 1.0 h at a 1:7 molar ratio of peptide:inhibitor. YX-I-1 inhibits primary nucleation, secondary nucleation and elongation of wt hIAP. YX-A-1 is a useful chemical tools to study hIAPP aggregation.

(-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits β-amyloid (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein.

gamma-secretase modulator 5 (compound 22d) is a brain-penetrant gamma-secretase modulator (GSMs) that inhibits the production of the aggregated amyloid β-peptide Aβ42 with an IC50 value of 60 nM. gamma-secretase modulator 5 can be used in the study of Alzheimer's disease.

Neuropeptide Y (NPY), a 36 amino acid peptide widely distributed within central nervous system neurons, is a neuroprotective agent against β-amyloid neurotoxicity which influences the synthesis and the release of nerve growth factor (NGF) by cortical neurons.

SQ-3 is a quinoline analogue, displays moderate selectivity for α-syn aggregates (Ki=39.3 nM) over β-amyloid (Aβ) aggregates (Ki=230 nM). [18F]SQ3 has basic properties as a lead compound for the development of a useful α-syn imaging probe.

CNB-001 is a pyrazole derivative of curcumin with neuroprotective properties, inhibits extracellular Aβ toxicity in hippocampal neurons with EC50 of 400 nM.

DDQ is a small molecule inhibitor of binding sites of Amyloid beta (Aβ) and Drp1, reduces interaction between Aβ and Drp1, shows anti-aging effects.

MeSC-04 is a potent α-Syn amyloid formation inhibitor, reduces the number and size of amyloid fibrils in vitro.

NPT200-11 is an orally bioavailable and brain penetrating alpha-synuclein (ASYN) misfolding and aggregation inhibitor.

SRI-42667 is a selective small-molecule Tau-SH3 interaction inhibitor with IC50 of 0.91 uM (Tau-FynSH3 interaction), prevents amyloid-β toxicity and network hyperexcitability.